Vertex Pharmaceuticals officer proposes $6.31M sale

The reported aggregate market value for the proposed sale is $6,307,134.98.

Available on EDGAR 11/06/2026 - 10:29 AM EST Accepted by SEC EDGAR 11/06/2026 - 10:29 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) lists 11,866 common shares for proposed sale for the account of Reshma Kewalramani, identified as an officer and director. Fidelity Brokerage Services LLC is named as broker. The notice gives an approximate sale date of November 6, 2026, and reports an aggregate market value of $6,307,134.98.

Key Figures

Common shares listed for sale: 11,866 shares Aggregate market value: $6,307,134.98 Shares in ESPP purchase entry: 69 shares +3 more

6 metrics

Common shares listed for sale 11,866 shares Proposed sale for Reshma Kewalramani’s account

Aggregate market value $6,307,134.98 Proposed sale

Shares in ESPP purchase entry 69 shares May 14, 2024

Shares in restricted stock vesting entry 1,744 shares February 24, 2025

Shares in ESPP purchase entry 53 shares May 14, 2025

Shares in restricted stock vesting entry 10,000 shares August 6, 2025

Key Terms

Rule 144, ESPP Purchase, Restricted Stock Vesting, aggregate market value

4 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

ESPP Purchase financial

"05/14/2024 | ESPP Purchase"

Restricted Stock Vesting financial

"02/24/2025 | Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VRTX shares does Reshma Kewalramani plan to sell?

The notice lists 11,866 common shares for sale for Reshma Kewalramani’s account. Fidelity Brokerage Services LLC is named as broker, and the approximate sale date is November 6, 2026.

What is the reported value of Reshma Kewalramani’s proposed VRTX sale?

The proposed sale is listed with an aggregate market value of $6,307,134.98.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001735944
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Kewalramani Reshma
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	11866	6307134.98	253537674	11/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/14/2024	ESPP Purchase	Issuer			69	05/14/2024	Cash
Common	02/24/2025	Restricted Stock Vesting	Issuer			1744	02/24/2025	Compensation
Common	05/14/2025	ESPP Purchase	Issuer			53	05/14/2025	Cash
Common	08/06/2025	Restricted Stock Vesting	Issuer			10000	08/06/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Reshma Kewalramani
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)